Inventor · disambiguated record
Roch Thibert
Also filed as: THIBERT ROCH
13 granted patents·8 pending applications·36 citations·filing 2001–2022
90Inventor score
Files withKARUNA THERAPEUTICS INC6ICO THERAPEUTICS INC2LAURENT PHARMACEUTICALS2MILLENDO THERAPEUTICS INC2THIBERT ROCH2
Top patents by PatentIndex Score
21 records- 0194US10925832B2Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2020·Granted Feb 23, 2021·5 cites·18 claims
- 0293US11452692B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2022·Granted Sep 27, 2022·2 cites·18 claims
- 0392US11890378B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2022·Granted Feb 6, 2024·1 cites·14 claims
- 0491US11471413B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·2 cites·21 claims
- 0589US10933020B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2019·Granted Mar 2, 2021·5 cites·46 claims
- 0683US10406127B2Solid oral formulation of fenretinideLAURENT PHARMACEUTICALS·Filed 2015·Granted Sep 10, 2019·3 cites·32 claims
- 0778US8703956B2Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acidBETANCOURT AIMESTHER·Filed 2012·Granted Apr 22, 2014·6 cites·26 claims
- 0877US10512619B2Solid oral formulation of fenretinideLAURENT PHARMACEUTICALS·Filed 2018·Granted Dec 24, 2019·3 cites·25 claims
- 0977US8980918B2Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acidATOPIX THERAPEUTICS LTD·Filed 2014·Granted Mar 17, 2015·3 cites·7 claims
- 1074US12151998B2Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoUNIV MICHIGAN REGENTS·Filed 2021·Granted Nov 26, 2024·0 cites·12 claims
- 1173US2021154146A1Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1266US6740666B2Substituted 8-arylquinoline phosphodiesterase-4 inhibitorsMERCK & CO INC·Filed 2001·Granted May 25, 2004·5 cites·4 claims
- 1366US2020255372A1Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoMILLENDO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1462US9546135B2Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoATTEROCOR INC·Filed 2015·Granted Jan 17, 2017·1 cites·8 claims
- 1554US10059660B2Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoMILLENDO THERAPEUTICS INC·Filed 2016·Granted Aug 28, 2018·0 cites·6 claims
- 1651US2024366616A1Soluble pharmaceutical compositions comprising salts of disubstituted 1, 2, 4-triazine compoundMINERALYS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1749US2021369615A1Solid oral formulations of amphotericin bICO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1848US2010210611A1Combination therapyTHIBERT ROCH·Filed 2008·Application pending·0 cites
- 1947US2007071692A1Aerosol powder formulationTHIBERT ROCH·Filed 2006·Application pending·0 cites
- 2044US2020155583A1Solid oral formulations of amphotericin bICO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2142US2006228410A1Flavored taste-masked pharmaceutical formulation made using a one-step coating processDUMONT HUBERT·Filed 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Roch Thibert files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →